Protalix BioTherapeutics (PLX) executive compensation, 2026 proxy

Dror Bashan, President and Chief Executive Officer, was paid $1.2M in 2025, down 24% from $1.5M the year before.

Filed
April 30, 2026
Annual meeting
June 25, 2026
Pay year
2025
Named executives
4
CEO total pay
$1.2M-24% vs prior year
CEO pay in equity
31%$359,032 in awards
2025 CEO Total Pay
$1,166,934Decreased from prior year
2025 Net Income Loss
-$6,604,000Net loss for fiscal 2025
2025 Total Shareholder Return
$95.74Based on $100 initial investment

How Bashan was paid

$1.2M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.

Salary34%Bonus24%Stock awards16%Option awards14%All other compensation11%

Named executive officers

ExecutiveTotal
Dror BashanPresident and Chief Executive Officer$1,166,934
Gilad MamlokSenior Vice President and Chief Financial Officer$405,225
Eyal RubinSenior Vice President and Chief Financial Officer$832,461
Yaron NaosSenior Vice President, Chief Operating Officer$575,769

What changed and why

  • $1.2MCEO total compensation decreased to $1,166,934 in fiscal 2025 from $1,527,792 in fiscal 2024.
  • $1.5MCompensation actually paid to the CEO was $1,524,580 in 2025.
  • $95.74Company total shareholder return decreased to $95.74 in 2025 from $105.62 in 2024.
  • $6.6MNet loss for fiscal 2025 was $6,604,000 compared to net income of $2,932,000 in 2024.
  • Gilad Mamlok succeeded Eyal Rubin as Chief Financial Officer during 2025.

About this page

Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.